Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:58AM EDT. Market open.
| Previous close | 231.58 |
| Open | 229.29 |
| Bid | 227.38 x 200 |
| Ask | 228.67 x 100 |
| Day's range | 227.75 - 231.95 |
| 52-week range | 189.44 - 319.76 |
| Volume | |
| Avg. volume | 1,228,777 |
| Market cap | 33.16B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 28.50 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
- Reuters
REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study. Shares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback in the search for new treatments for ALS, a rare neurodegenerative disease that affects the voluntary control of limbs and leads to breathing trouble.
- Investor's Business Daily
Biogen Stock Continues Its 24% Sprint On A Twist In Alzheimer's Treatment
Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.
© 2024 Yahoo. All rights reserved.